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Abstract 
 
Aims: This paper is an elaborate and quantitative attempt to construct medically applicable 
mathematical models and derive criteria for efficacious Highly Active Anti-Retroviral Therapy 
(HAART) protocol for an AIDS patient. The patho-physiological dynamics of Human 
Immuno-deficiency Virus type 1 (HIV-1) induced AIDS during HAART is modeled by a 
system of non-linear deterministic differential equations. The physiologically relevant and 
clinically plausible equations depict the dynamics of uninfected CD4+ T cells (x1), HIV-1 
infected CD4+ T cells (x2), HIV-1 virions in the blood plasma (x3), HIV-1 specific CD8+ T cells 
(x4), and the concentration of HAART drug molecules (x5). The major objective of this research 
is to construct an elaborate mathematical model that depicts patho-physiodynamics of HIV-1 
virions during HAART. The derived therapeutic criteria are expressed in terms of clinically 
measurable physiological parameters. Investigative computer simulations which describe 
certain aspects of HIV-1 dynamics during HAART are also presented in the paper. 
Study Design: The mathematical model is constructed based on contemporary research data 
condensed from the clinical literature on HAART of AIDS. A system of coupled non-linear 
deterministic differential equations are used to characterize the patho-physiodynamics of 
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HAART during the post chronic phase. The mathematical analysis of the model equations and 
the computer simulations are performed with regard to HAART protocols with constant 
continuous intravenous and transdermal drug infusions. A syncytium term with stoichiometric 
coefficient is introduced into the model to account for the formation of large multinucleated 
gp120 bearing CD4+ T cells that are observed in some AIDS patients. By assigning a zero 
value to the stoichiometric coefficient, the role of syncytium is abrogated. 
Place and Duration of Study: This research was done at Fayetteville State University, North 
Carolina USA, and is sponsored by the FSU Mini-Grant Award and the HBCU Graduate 
STEM Grant. The research was conducted during the Spring of 2012. 
Methodology: The deterministic nonlinear dynamics of HIV-1 AIDS equations are analyzed 
using the techniques of dynamical system theory, principles of linearized stability, non-linear 
system theory, and other relevant mathematical techniques. The clinically desirable equilibrium 
states, their local existence, and global stability are analyzed. Investigative computer 
simulations are performed illustrating some physiological outcomes. 
Results: The therapeutic outcomes are presented in the form of theoretical criteria which are 
obtained from mathematical analysis of the model equations. In particular, the critical 
parameters which govern the dynamics of HIV-1 virions during HAART are clearly identified. 
Some clinical implications of HAART are elucidated in the computer simulations using 
hypothetical physiological parametric configurations.   
Conclusion: This research has demonstrated the existence of plausible criteria under which 
HIV-1 virions can be annihilated using HAART. The latent HIV-1 virion reservoirs are 
implicated in unsuccessful scenarios of HAART. It has also been demonstrated that the rate 
constants associated with activation of lymphocytes by cytokine interleukin-2 (IL-2) play a 
significant role in determining the efficacious outcomes of HAART. 
Keywords: HIV-1 patho-physiodynamics, mathematical modeling, HAART therapy, AIDS cure 
criteria, Michaelis-Menten kinetics. 
 
AMS Subject Classification: 93A30; 93D05; 93D20; 34A34; 92C42; 92C35. 
 
1 Introduction 
 
Highly Active Anti-retroviral Therapy (HAART) is currently the most therapeutically efficacious 
treatment protocol for treating the Acquired Immunodeficiency Syndrome (AIDS). HIV-1 virions 
induce AIDS by orchestrating an irreversible destruction of the CD4+ T cells which then paralyze 
the immune system of the HIV-1 positive person. The major objectives of HAART therapy are the 
prolongation and improvement of the long-term life quality of patients; optimization of therapy 
such as to suppress the HIV-1 viral load to below 50 copies of HIV-1 RNA; reconstitution of the 
patients’ immune system such that the CD4+ T cells proliferate to carrying capacity; and 
minimization of drug toxicity. HAART treatment protocol consists of nucleoside reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, anti-
fungals /anti-bacterials and in future, integrase inhibitors. The reverse transcriptase inhibitors 
prevent reverse transcription of HIV-1 specific DNA. The protease inhibitors are antagonistic to 
maturation and formation of new HIV-1 virions. The possible role of integrase inhibitors is to 
prevent the integration of HIV-1 viral DNA into the patients’ DNA [1,2]. 
 
In order to achieve the therapeutic goals of HAART, it is plausible to involve the techniques of 
mathematical modeling. Before the advent of HAART, the primary focus of the mathematical 
modelers is to quantitatively analyze the observed patho-physiodynamics of HIV-1 infection in 
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the AIDS patients. These earlier research papers involve the pioneering work of Perelson et al. [3], 
Nowark et al. [4], and other contributors [5,6]. 
 
A recent paper by Nani and Jin [7] provided some physiological criteria under which HIV-1 
virions in an AIDS patient can be annihilated during HAART.  
 
Some of the earlier mathematical modeling publications focus on single-drug AIDS therapy using 
Zidovudine (INN) or Azidothymidine (AZT) [8]. Then the advent of Active Retro-viral Therapy 
(ART) and the associated clinical limitation let to the development of HAART treatment protocols. 
In spite of the initial success of HAART, there are clinically measurable and observable 
shortcomings in the treatment of AIDS [9].  In particular, HAART is not successful in about 40% 
of AIDS patients because of drug-induced toxicity and complications of treatment. HAART 
protocols have been clinically observed to have limited therapeutic efficacy due to 
biochemical/clinical drug resistance, short drug half-life, low bio-availability and blood plasma 
toxicities.  
 
Mathematical modeling provides a quantitative and rational approach to solve the therapeutic 
efficacy problems associated with HAART. In particular, the models focused on finding optimal 
therapeutic schedules, the roles of latent viral reservoirs as well as minimizing of toxic side effect 
[5,6,8,10-14]. 
 
Mathematical models which incorporate the explicit computation of the cure rate of HIV-1 
induced AIDS during HAART include models by [15-17]. 
 
During HAART, the major obstacle to total viral eradication is the existence of viral reservoirs 
and retroviral latency [18]. Retroviral latency is defined as an integrated pro-virus with no active 
transcription. This is associated with low-level chronic viral and persistent cryptic HIV-1 
replication. These processes lead to viral persistence after initial successful HAART [18]. 
Mathematical models which demonstrate persistence due to viral reservoirs have been constructed 
by Nani and Jin [15,16]. Other models which elegantly address the role of viral reservoirs in 
persistence include papers by Rong and Perelson in [19], Kim and Perelson in [20], and Sedaghat, 
Siliciano and Wilke in [21]. 
 
Optimal therapies that will minimize side effects have been investigated by many authors in        
[3-5,7,8,14,22,23]. Zaric et al. in 1998 [24] presented a model which was focused on the 
simulation of protease inhibitors and role of drug resistant HIV-1 virions. Stengel in [22] 
presented a mathematical model of HIV-1 infection and HAART which demonstrated the efficacy 
of a mathematically optimal therapy. Caetano and Yoneyama in [11] constructed a HAART model 
which incorporated the roles of latently infected CD4+ T cells, and discussed how the reverse 
transcriptase and protease inhibitors affected HIV-1 dynamics during HAART, using the LQR, 
Scheme. In particular, Hattaf and Yousfi incorporated the basic reproductive number R0 in 
determination of optimal HIV therapy in [25]. In a separate paper, the same authors constructed a 
delayed differential equation model of HIV-1 dynamics during therapy in [26]. They employed a 
numerical algorithm and Pontryagin’s Maximum Principle in determination of the optimal 
therapies. In a future paper, we will use Pontryagin’s Minimal Principle to construct admissible 
optimal therapies such as to minimize the toxicity of the drug but maximize the therapeutic 
efficacy of HAART. 
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In this paper, an elaborate mathematical model will be constructed which will incorporate 
physiologically plausible effects such as Michaelis-Menten kinetics, role of HIV-1 latent viral 
reservoirs, continuous transdermal drug delivery, and the implicit lymphocyte proliferation 
induction by the CD4+ T cells. The activation and proliferation is accomplished by a paracrine and 
autocrine processes which are mediated by the cytokine interleukin-2, secreted by the CD4+ T 
cells.  A special feature of the current paper is the inclusion of the syncytium production term to 
the HIV-1 virion compartment. It has been shown by Koot et al. [27] in that syncytium inducing 
HIV-1 variants, occurring 2 years before progression to AIDS, on an average, significantly 
increase the rate of CD4+ declines. The destruction mechanism of CD4+ and CD8+ T cells due to 
syncytium formation and other mechanisms has been described by Shut et al. [28]. These features 
are incorporated in the current paper by assigning two separate cell loss rates. The HIV virions can 
also disintegrate by releasing the soluble HIV-1 envelope protein gp120 into the blood plasma 
which can attach to uninfected CD4+ T cells, causing attack by antibodies thereby increasing the 
rate of decline of immuno-competent CD4+ T cells. Mathematical structures are used in the 
current model to demonstrate these aspects of HIV-1 and CD4+ T cell dynamics. 
 
Several authors investigated the consequences of structured long-term and short-term treatment 
interruptions during HAART [9-11,14]. The current model will discuss these consequences by 
means of simulations.  
 
The current paper will be divided into eight sections. The first section gives the introduction into 
HAART therapy and provides the basis for current research. This is followed by presentation and 
discussion of the model parameters in Section 2. In Section 3 the mathematical model of HAART 
therapy will be constructed. Also the necessary and sufficient criteria for annihilation of HIV-1 
virions during HAART will be presented in sections 4, 5, and 6. In Section 7, clinically plausible 
computer simulations will be exhibited. Section 8 will conclude the paper. 
 
2 Parameters 
 
In this section, the physiological variable and parameters of the HAART model equations will be 
defined and explained. It must be emphasized that some of these parameters are biologically 
measurable or can be estimated using clinical techniques. In clinical experience, these parameters 
are different from patient to patient depending on their patho-physiological conditions. 
 
A list of model parameters, constants, and variables is shown as follows.  
 
x1 : The number density of non-HIV-1-infected CD4+ helper T-lymphocytes per unit volume 
x2 : The number density of HIV-1 infected CD4+ helper T-lymphocytes per unit volume 
x3 : The number density of HIV-1 virions in the blood plasma per unit volume 
x4 : The number density of HIV-1 specific CD8+ cytotoxic T-lymphocytes per unit volume 
x5 : The concentration of drug molecules of the HAART treatment protocol 
S1 : Rate of supply of un-infected CD4+T4-lymphocytes  
S2 : Rate of supply of latently infected CD4+ T4-lymphocytes 
S3 : Rate of supply of HIV-1 virions from macrophage, monocytes, microglial cells and 
other lymphoid tissue different from T4-lymphocytes 
S4 : Rate of supply of CD8+ T8 lymphocytes from the thymus 
D :  Rate of HAART drug infusion by transdermal delivery 
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ai,bi : Constant associated with activation of lymphocytes by cytokine interleukin-2 (IL-2) (i 
=1, 2, 3, 4) 
c :  Rate of HAART drug degradation and excretion 
αi : Constant associated with HIV-1 infection of CD4+ T4 helper cells (i =1, 2, 3) 
β1 : The number of HIV-1 virions produced per day by replication and budding in CD4+ T4 
helper cells 
β2 : Rate constant associated with replication and “budding” of HIV-1 in syncytia CD4+ T4 
helper cells per day per microliter (µl) and released into the blood plasma 
β3 : The number of HIV-1 virionsproduced per day by replication and “budding” in non-
syncytia CD4+ T4 helper cells and released into the blood plasma 
ηi : Constant depicting the rate of which HIV-1 virions incapacitate the CD8+ T8 cytotoxic 
cells (i =1, 2) 
(σ0,λ0) : Michaelis-Mentennonlinear metabolic rate constants associated with HAART drug 
elimination 
(σi,λi) : Michaelis-Mentennonlinear metabolic rate constants associated with HAART drug 
pharmacokinetics (i =2, 3) 
ξI : Cytotoxic coefficient where 0 ≤ξi≤ 1 (i=  2, 3) 
qi : Constant depicting competition between infected and un-infected CD4+ T4 helper cells(i 
=1, 2) 
ki : Constant depicting degradation, loss of clonogenicity or  “death”(i =1, 2, 3, 4) 
k5 : Rate constant depicting exponential drug elimination pharmacokinetics 
ei0 : Constant depicting death or degradation or removal by apoptosis (programmed cell 
death)(i =1, 2, 3, 4) 
Ki : Constant associated with the killing rate of infected CD4+ T4 cells by CD8+  T8 
cytotoxic lymphocytes(i =1, 2) 
 
All the parameters are positive. 
 
3 Model Equations 
 
3.1 Description of the Model Equations 
 
The HIV-1 patho-physiological dynamics during HAART therapy can be modeled using the 
following system of non-linear ordinary differential equations. A detailed description of the 
dynamics of the model variables x1, x2, x3, and x4 can be found in Nani and Jin [15]. 
 
The model includes the following clinical improvements: 
 
(i) The drug delivery uses transdermal, stealth-liposome encapsulated drug delivery, instead 
of the matrix tablet form because of improved therapeutic efficacy and reduced gastro-
intestinal toxicity [12].  It is also assumed that elastic liposomes are formulated and 
selectively targeted such as to reduce toxicity to non-HIV-1-infected CD4+ T cells (x1) 
and CD8+ cytotoxic T cells (x4). 
(ii) The HAART drug is such that each renal excretion and body clearance rate follows 
Michaelis-Menten kinetics. 
(iii) 111 ),( xbjjj jexxaxxg −= for j=(1, 2, 4)  
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 This function depicts the process of lymphocyte activation which is mediated by x1      
(CD 4+) T helper cells. These cells secrete a cytokine called interleukin-2. 
(iv) The periodic input function f(t)= can be depicted by the following plot: 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
    for constant continuous input  
    for periodic input 
(3.1) 
 
 
 
 
3.2 Boundedness and Invariance of Non-negativity of Solutions 
 
In this subsection theoretical conditions will be constructed under which solutions to the HAART 
mathematical model equations are well-posed, ultimately bounded, and exhibit invariance of non-
negativity for all ),0[],[ 0 ∞=ℜ⊂∈ +Ttt . In this case, t0, and T are defined respectively as times 
at which HAART therapy begins and terminates.  
 
Theorem 3.1 Consider  
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(i) 
 
Let 
 
(ii) 
   
    (3.2) 
 
where 
 
 
and 
},min{ 5320 kδδδδ ++= , 
 
Then there exists a T0>0 such that for T0<t<∞, all solutions to the HAART model equations (3.1) 
with initial values xi0∈ℜ5+={xi∈ℜ | xi≥0, i=(1,2,3,4,5)} are ultimately bounded, dissipative, and 
will eventually enter the non-negatively invariant region Ω. In particular, the solutions are trapped 
in the region Ω for all +ℜ⊂> 0Tt  
 
Proof.  Using the result from Nani and Jin in [7], let   
 
    
  (3.3) 
 
 
The non-linear system (4.1) can be converted to the following non-linear differential inequalities: 
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Theorem [[Kamke: (ref. [29] Theorem. 2.6.3)]] 
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Suppose 
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Applying Kamke theorem to the system (3.4), the following inequalities hold. 
 
 
 
(3.5) 
 
 
 
 
In particular, the following results can be obtained. 
 
 
    
    
   (3.6) 
 
 
Thus, Ω is non-negatively invariant and the system is ultimately bounded, dissipative, with the 
bounds defined by the following equations.  
 
 
    
 
   (3.7) 
 
 
 
As a consequence of (3.7), the orbits of xi(t) are uniformly bounded.  
 
This completes the proof.                 
 
4 The Equilibria and Computation of the Jacobian Matrices 
 
In this section, the model equations will be restricted to the case for which the drug input function 
has the form f(t) = 1. Thus, (3.1) reduces to a system (4.1) of deterministic, non-linear, and 
autonomous ordinary differential equations. 
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   (4.1) 
  
 
The physiological outcomes or the equilibria during constant continuous transdermal HAART 
therapy occur when ix& = 0 for i=1, 2, 3, 4, 5. 
 
4.1 Local Existence Criteria for Clinically Relevant Steady States of HAART 
 
In this subsection, a subset of clinically relevant states or the possible patho-physiological 
outcomes from constant continuous transdermal HAART therapy are listed and analyzed.  These 
outcomes are labelled Ei for i = 1, 2, …, 10. The local existence criteria are labelled Ci. 
 
(i) E1= [0, 0, 0, 0, x5] 
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This equilibrium represents the scenario in which HAART annihilates the HIV-1 virions, the non-
infected CD4+, the infected CD4+, and CD8+ T cells. The immuno-compromised patient may 
become incapacitated with opportunistic infections.   
 
(ii) E2= [0, 0, 0, x4, x5] 
 
C2: 





Ω∈=−
+
−
==−
555
50
50
0
0
}3,2,1{0
xforxk
x
xD
ieS ii
λ
σ
 
 
This equilibrium is similar to case (i) except that HIV-1 specific CD8+ cells are now present in the 
steady state.    
 
(iii) E3= [x1, 0, 0, x4, x5] 
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This equilibrium corresponds to a scenario of successful HAART protocol in which the steady 
state consists of some uninfected CD4+ T cells, HIV-1 specific CD8+ T cells, and some drug 
residue.   
 
(iv) E4= [x1, 0, 0, 0, x5] 
 
C4: 








Ω∈=−
+
−
==−
=−−+ −
5155
50
50
0
1011
2
111
,0
}4,3,2{0
011
xxforxk
x
xD
ieS
exkexaS
ii
xb
λ
σ
 
 
This equilibrium also corresponds to a scenario of successful HAART protocol in which the 
steady state consists of some uninfected CD4+ T cells and some drug residue but no HIV-1 
specific CD8+ T cells.   
 
(v) E5= [0, x2, x3, 0, x5] 
 
        C5: 











Ω∈=−
+
−
+
−
+
−
=
+
−−−++
=
+
−−−−
==−
53255
53
533
52
522
50
50
53
5333
3033333223
52
5222
2031222
0
,,0
0
0
}4,1{0
xxxforxk
x
xx
x
xx
x
xD
x
xx
exkxxxS
x
xx
exxkS
ieS ii
λ
σ
λ
σ
λ
σ
λ
σξββ
λ
σξβ  
 
This equilibrium exhibits a failure of HAART protocol. In particular, the HIV-1 infected CD4+ T 
cells and HIV-1 virions populate the steady state in addition to some drug residue whereas the 
non-infected CD4+ and CD8+ T cells are annihilated.   
 
(vi) E6= [0, 0, x3, 0, x5] 
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This equilibrium also depicts a case of therapeutic failure of HAART because HIV-1 virions still 
remain in the blood plasma of the patient.   
 
(vii) E7= [0, x2, 0, 0, x5] 
 
C7: 









Ω∈=−
+
−
+
−
=
+
−−−
==−
5255
52
522
50
50
52
5222
20222
0
,0
0
}4,3,1{0
xxforxk
x
xx
x
xD
x
xx
exkS
ieS ii
λ
σ
λ
σ
λ
σξ
 
  
 
 
 
 
 
Nani and Jin; BJMCS, 5(2): 262-299, 2015; Article no.BJMCS.2015.018 
 
272 
 
This equilibrium represents another a scenario of unsuccessful HAART protocol because HIV-1 
infected CD4+ T cells and drug residue populate the steady state.  
 
(viii) E8= [x1, x2, 0, 0, x5] 
 
C8: 










Ω∈=−
+
−
+
−
=
+
−−−−+
=−−−+
==−
−
−
52155
52
522
50
50
52
5222
20222122122
1021111
2
111
0
,,0
0
0
}4,3{0
12
11
xxxforxk
x
xx
x
xD
x
xx
exkxxqexxaS
exxqxkexaS
ieS
xb
xb
ii
λ
σ
λ
σ
λ
σξ
 
 
This equilibrium is not clinically desirable because of existence of HIV-1 infected CD4+ T cells.  
 
(ix) E9= [x1, x2, 0, x4, x5] 
 
 
 
 
 
C9:  
 
 
 
 
 
This equilibrium is another scenario of therapeutic failure of HAART protocol because HIV-1 
infected CD4+ T cells are all present.   
 
(x) E10= [x1, x2, x3, x4, x5] 
 
The steady state E10 depicts a person who is living with AIDS. In this case, the model exhibits 
persistence and the viral titer is not sufficient to annihilate the immune system. The criteria for 
persistence of HIV-1 AIDS during HAART will be discussed in Theorem 5.5.  
 
There are some other steady states which are not listed because they are less clinically interesting.  
 
4.2 Computation of the Jacobian Matrices 
 
Using the Hartman-Grobman theorem, it is possible to investigate the therapeutic efficacy of 
HAART and the physiological stability of HIV-1 AIDS disease dynamics associated with the 
model equations, by linearizing the system (4.1) in the neighborhood of the equilibria.  
 
The Jacobian matrix of linearization near any physiological outcome is denoted symbolically by 
 
[ ] { } 5,4,3)(: 5555 =ℜ∈= ×× kMaEJ ijk
     
  
 











Ω∈−
+
−
+
−
=−−−+
=−
=
+
−−−−−+
=−−−+
−
−
−
532155
52
522
50
50
40444224144
303
52
5222
20421222122122
1011211
2
111
,,,
0
0
0
0
14
12
11
xxxxforxk
x
xx
x
xD
exkxxKexxaS
eS
x
xx
exxKxkxxqexxaS
exkxxqexaS
xb
xb
xb
λ
σ
λ
σ
λ
σξ
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52
53
333
2
52
222
2
50
00
55
54
53
53
53
52
52
52
51
45
432221444
4243
4242
144441
2
53
333
35
3134
53
533
3411332233
3232
3331
2
52
2222
25
2124
11223
52
522
412121222
22122221
15
14
1113
1112
12131111111
)()()(:
0:
:
:
0:
0:
:
:
:
)1(:
)(:
:
:
:
:
)(:
:
:
:
)1(:
0:
0:
:
:
)2(:
14
14
12
12
11
k
x
x
x
x
x
a
a
x
x
a
x
x
a
a
a
kxxKexaa
xa
xKa
exbxaa
x
a
xa
x
xkxxxa
xa
xa
x
x
a
xKa
xa
x
x
xKkxqexaa
xqexbxaa
a
a
xa
xqa
kxqxexbxaa
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xb
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−
+
−
+
−
+
−=
=
+
−=
+
−=
=
=
−−−=
−=
−=
−=
+
−=
−=
+
−−−−+=
=
−=
+
−=
−=
−=
+
−−−−=
−−=
=
=
−=
−=
−−−−=
−
−
−
−
−
λ
λσ
λ
λσ
λ
λσ
λ
σ
λ
σ
η
η
λ
λσξ
η
λ
σξηαββ
β
α
λ
σλξ
βα
λ
σξ
α
α
In particular, the aij entries are defined as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
       
 
 
 
(4.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Jacobian matrices for the steady states E3, E4, E5 are respectively listed as follows: 
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





















−
+
−
+
−
+
−
−
+
−
+
−−
−
+
−−
−
=
52
50
00
53
53
52
52
4
2
53
333
53
533
33
1
52
522
2
1
51
)(00
0000
)(000
000
0000
]},0,0,0,0[{
k
xx
x
x
x
k
xx
xk
x
xk
k
xEJ
λ
λσ
λ
σ
λ
σ
λ
λσξ
λ
σξβ
βλ
σξ
        (4.3) 
 






















−
+
−
+
−
+
−
−−−
+
−
+
−−−
−
+
−−−
−
=
52
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00
53
53
52
52
4424244
2
53
333
53
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3413
1
52
522
412
1
542
)(00
0
)(000
000
0000
]},,0,0,0[{
k
xx
x
x
x
kxxKxa
xx
xkx
x
x
xKk
k
xxEJ
λ
λσ
λ
σ
λ
σ
η
λ
λσξ
λ
σξηβ
βλ
σξ
   (4.4) 
 
























−
+
−
+
−
+
−
−−−−
+
−
+
−−−−
−
+
−−−−
−−−−
=
−−
−
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00
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41442421444
2
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)(00
0)1(
)(000
000
00)2(
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12
11
k
xx
x
x
x
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x
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λ
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λ
σ
λ
σ
η
λ
λσξ
λ
σξηαβ
βαλ
σξ
α
           
(4.5) 





















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−
+
−
+
−
+
−
−
+
−
+
−−−
−
+
−−−
−−−−
=
−
−
−
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2
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533
3133
112
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)(000
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(4.6) 
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





















−
+
−
+
−
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−
+
−
+
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−−−
+
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+
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+
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2
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00
53
53
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2
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31
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2
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22222
31121
5325
)()()(00
0000
)(
)(
0000
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k
x
x
x
x
xx
x
x
x
kxxK
x
x
x
xkxxx
x
x
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λ
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σξβββα
λ
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(4.7) 




















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
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−
+
−
+
−
+
−
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+
−
+
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+
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2
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527
)()(00
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)(000
)(
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]},0,0,,0[{
k
x
x
xx
x
x
x
kxK
xx
xkx
x
x
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x
xkxqxa
kxq
xxEJ
λ
λσ
λ
λσ
λ
σ
λ
σ
λ
λσξ
λ
σξββ
λ
σλξβλ
σξ
 
(4.8) 
 


























−
+
−
+
−
+
−
+
−
−+−−−
+
−
+
−−−
−+
+
−−−
+
−−−−+−
−−−+−
=
−−
−−
−
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52
222
2
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00
53
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52
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4221442421444
2
53
333
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533
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2
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2222
21112
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11111211111
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)()(00
0)1(
)(000
)()1(
00)2(
]},,0,,[{
1414
1212
11
k
x
x
xx
x
x
x
kxKexaxxKexbxa
x
x
xkx
xx
x
x
xKx
x
x
xKkxqexaxqexbxa
xxqkxqexbxa
xxxxEJ
xbxb
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λ
λσ
λ
λσ
λ
σ
λ
σ
η
λ
λσξ
λ
σξη
αββ
λ
λσξβαλ
σξ
α
(4.9) 
 
5 Necessary Criteria for Local Stability of Equilibria during 
HAART 
 
Let E = {E1, E2, …,E10} denote the set of some clinically relevant equilibria of model equations 
(4.1). In this section, the local stability of E4, E5, E1, and E3 will be analyzed using the principles 
of linearized stability of autonomous ordinary differential equations. In particular, the necessary 
mathematical criteria for certain therapeutic outcomes during HAART are computed and 
presented in the form of theorems.  
 
5.1 Local Stability of ]ˆ,0,0,0,ˆ[ 514 xxE =
 
 
The Jacobian matrix associated with ]ˆ,0,0,0,ˆ[ 514 xxE =  is defined as 
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555352
44
3533
2322
131211
514
ˆ0ˆˆ0
0ˆ000
ˆ0ˆ00
00ˆˆ0
00ˆˆˆ
:]}ˆ,0,0,0,ˆ[{
aaa
a
aa
aa
aaa
xxEJ =
 
 
 
 
 
 
 
 
If the condition 
2
1
1ˆ α
β
=x is imposed on the Jacobian matrix above, then 0ˆ23 =a . The eigen-
spectrum associated with the Jacobian matrix is defined as  
 
},,{}2,1,0ˆˆ|{]})ˆ,0,0,0,ˆ[{( 543212514 λλλλλλσ ∪==++= iaaxxEJ i  
 
where 
 








=
=
=
−=
+−=
445
224
113
533555332
55331
ˆ
ˆ
ˆ
ˆˆˆˆˆ
)ˆˆ(ˆ
a
a
a
aaaaa
aaa
λ
λ
λ
      
   
Theorem 5.1. Suppose C4 in Section 4.1 holds, and: 
 
(i) 







=
>
>
2
1
1
2
1
ˆ
0ˆ
0ˆ
α
β
x
a
a
        (5.1) 
(ii)  







<−=
<
+
−−−=
<−−=
−
−
−
0ˆˆ
0 
ˆ
ˆ
ˆˆˆ
0)ˆ2(ˆˆ
4
ˆ
1444
52
522
212
ˆ
1222
1
ˆ
111111
14
12
11
kexaa
x
xkxqexaa
kexbxaa
xb
xb
xb
λ
σξ
    (5.2) 
 
Then the HAART therapeutic outcome ]ˆ,0,0,0,ˆ[ 514 xxE = exists and it is a local attractor.   
 
Proof. Theeigen-values of ]}ˆ,0,0,0,ˆ[{ 514 xxEJ satisfy the determinantal equation: 
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0
ˆ0ˆˆ0
0ˆ000
ˆ0ˆ00
00ˆˆ0
00ˆˆˆ
det
|]}ˆ,0,0,0,ˆ[{|det
555352
44
3533
2322
131211
514
=
−
−
−
−
−
=−
λ
λ
λ
λ
λ
λ
aaa
a
aa
aa
aaa
IxxEJ
 
 
Using the Laplace expansion technique for computation of determinant, the characteristic eigen-
value polynomial is given by  
 
 
0
ˆˆ
ˆˆ
det)ˆ)(ˆ)(ˆ())(,(
5553
3533
4422114 =
−
−
−−−= λ
λλλλλ
aa
aa
aaaEJp
 
But 
 
 
5553
3533
5533
2
5553
3533
ˆˆ
ˆˆ
det)ˆˆ(:
ˆˆ
ˆˆ
det
aa
aa
aa
aa
aa
++−=
−
− λλλ
λ
 
 
Let 
 
5553
3533
2
55331
ˆˆ
ˆˆ
detˆ
)ˆˆ(ˆ
aa
aa
a
aaa
=
+−=
       (5.3) 
 
The eigen-spectrum is therefore given by  
 
 },,{}2,1,0ˆˆ|{]})ˆ,0,0,0,ˆ[{( 543212514 λλλλλλσ ∪==++= iaaxxEJ i  
where 
445
224
113
2
2
112
2
2
111
ˆ
ˆ
ˆ
)ˆ4ˆˆ(
2
1
)ˆ4ˆˆ(
2
1
a
a
a
aaa
aaa
=
=
=
−+−=
−−−=
λ
λ
λ
λ
λ
 
 
The conditions (5.1) and (5.2) guarantee that the eigen-values associated with the equilibrium E4 
have negative real part by virtue of Routh-Hurwicz criteria [7]. Hence, the equilibrium is locally 
asymptotically stable and a local attractor as well as a hyperbolic sink. This theorem establishes 
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the local existence and local stability of a clinically desirable physiological outcome of HAART 
protocol. 
       
Clinical Implication 5.1. The criteria (5.1) and (5.2) guarantee a temporary cure for the AIDS 
patient. There will be a finite time interval during which the HIV-1 virions will be annihilated 
from the patient’s blood plasma. This will however be short-lived because the rest point E4[x1, 0,0, 
0, x5] may become unstable and the criteria for temporal cure are violated. It is possible for 
therapeutic criteria to be derived to maintain the patient to be permanently free of AIDS, which we 
shall discuss in Theorem 5.5. 
 
5.2 Local Stability of ],0,,,0[ 5325 xxxE
(((
=  
 
In this subsection, the local existence and stability of ],0,,,0[ 5325 xxxE
(((
= will be analyzed. 
The results are summarized in the following theorem. 
 
Theorem 5.2. Suppose   
 
(i) Existence criteria C5 for equilibrium ],0,,,0[ 5325 xxxE
(((
= holds.  (5.4) 
(ii) Let ]}),0,,,0[{( 5325 xxxEJ (((σ be the eigen-spectrum of 
 
 
          
  (5.5) 
 
 
 
 
with the ija
(
are depicted by (4.7). 
 
such that 
 },{}3,2,1,0|{]}),0,,,0[{( 54322135325 λλλλλλσ ∪==+++= iaaaxxxEJ i ((((((  (5.6) 
 
Where 
 
445
114
555352
353332
252322
3
3332
2322
3331
2522
5553
3533
2
555352
353332
252322
1
det
detdetdet
a
a
aaa
aaa
aaa
a
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aa
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aa
a
aaa
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(
(((
(((
(((
(
((
((
((
((
((
((
(
(
=
=
−=
++=










−=
λ
λ
    (5.7) 
555352
44
3534333231
2524232221
11
5325
00
0000
0000
:]},0,,,0[{
aaa
a
aaaaa
aaaaa
a
xxxEJ
(((
(
(((((
(((w(
(
(((
=
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Then the rest point ],0,,,0[ 5325 xxxE
((( is locally asymptotically stable hyperbolic sink and a local 
attractor if  
 
32131 ,0,0 aaaaa
(((((
>>>       (5.8) 
 
Proof. The eigen-values associated with ],0,,,0[ 5325 xxxE
(((
satisfy  
 
 
0|]},0,,,0[{|det 55325 =− IxxxEJ λ(((  
 
Using the Laplace expansion technique of determinants leads to (5.6) with the Routh-Hurwicz 
coefficients depicted by (5.7). The conditions specified in (5.8) guarantee that the equilibrium is 
locally asymptotically stable and a local attractor.     
     
Clinical Implication 5.2. This theorem depicts the conditions for one of the worst scenarios 
during AIDS therapy using continuous infusion HAART. If the conditions (5.4) and (5.8) hold, 
then the HAART therapy annihilated all the uninfected CD4+ T cells, and HIV-1 specific 
cytotoxic CD8+ T cells. Consequently, the immune system of the AIDS patient becomes 
incapacitated and the patient becomes the target of opportunistic infections. However, this 
situation may not last very long but could be fatal.  
 
5.3 Local Stability of ]~,0,0,0,0[ 51 xE =
 
  
In this subsection, the local existence and local stability of the non-clinically efficacious 
equilibrium E1 will be discussed. Theoretical criteria under which ]~,0,0,0,0[ 51 xE =  is locally 
stable will be derived. The results are summarized in the following theorem. 
 
Theorem 5.3. Suppose 
 
(i) The criterion C5 holds for the local existence of ]~,0,0,0,0[ 51 xE =  
(ii) Let         
   










=
555352
3533
2322
~~~
~~0
0~~
~
aaa
aa
aa
M        
   
Such that 
 
Ma
aaa
aa
aa
a
MTracea
~det~
)~~(~
~~
~~
det~
)~(~
3
553322
5553
3533
2
1
−=
++=
−=
      (5.9) 
 
Then the equilibrium E1 is hyperbolic sink, locally asymptotically stable, and a local attractor if  
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 321321
~~~
,0~,0~,0~ aaaaaa >>>>  
 
Proof. Let λI for i= {1, 2, 3, 4, 5} denote the eigen-values corresponding to the Jacobianmatrix  
]},0,0,0,0[{ 51 xEJ given by (4.3). Then the corresponding eigen-spectrum is given by the 
equation: 
 
 },{}3,2,1,0~~~|{]})~,0,0,0,0[{( 543221351 λλλλλλσ ∪==+++= iaaaxEJ i
 
 
Where 321
~
,
~
,
~ aaa are specified in (5.9). But 0~ 1114 <−== kaλ and 0~ 4445 <−== kaλ . 
 
The conclusion of the theorem follows immediately after application of the Routh-Hurwicz 
criteria.  
 
Clinical Implication 5.3. If the HAART protocol used for the AIDS patient is such that condition 
(5.9) is satisfied, then the patient experiences extreme immune system cytotoxicity in which the 
uninfected CD4+ T cells, HIV-1 specific cytotoxic CD8+ T cells, HIV-1 virions, and HIV-1 
infected CD4+ T cells are all decimated. This is not a therapeutically desirable clinical outcome, 
because the patient may become severely incapacitated. To avoid this scenario, the HAART 
therapy must implemented in such a way that criterion (5.9) is violated. 
 
5.4 Local Stability of ],,0,0,[ 5413 xxxE =
 
 
The local existence and local stability of the equilibrium ],,0,0,[ 5413 xxxE = will be analyzed 
in this subsection. The clinical relevance of the theoretical therapeutic criteria will be discussed.  
 
Let ]},,0,0,[{( 5413 xxxEJσ be the eigen-spectrum for the Jacobian matrix 
]},,0,0,[{( 5413 xxxEJ such that }5,4,3,2,1,0|)(|det|{]}),,0,0,[{( 35413 ==−= iIEJxxxEJ i λλσ  
 
Theorem 5.4. Suppose  
 
(i) The local existence criteria C3 holds for E3 
(ii)   
42
1
1
1
b
x ==
α
β
 
(iii) 





<
+
−−−−
<−−
−
−
0
0)2(
52
522
4121212
11111
12
11
x
x
xKkxqexa
kexbxa
xb
xb
λ
σξ  
(iv) 










=
5553
4443
3533
0
0
0
aa
aa
aa
M  
 
with 
 ],[]3,2,1,0|[))(( 54322133 λλλλλλσ ∪==+++= iaaaEJ i  
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where 
 
0
0
det
0
detdet
0
0
det
)(
225
114
3
4443
33
5553
3533
55
44
2
1
<=
<=
−=
++=
−=
a
a
Ma
aa
a
aa
aa
a
a
a
MTracea
λ
λ
 
 
Then the equilibrium E3 exists locally and is a local attractor if 
 
 321321 ,0,0,0 aaaaaa >>>>      (5.10) 
    
Proof. Consider the Jacobian matrix (4.5) associated with the equilibrium E3. By imposing the 
condition (ii) of the theorem and computing the eigen-values using the Laplace expansion 
technique, it can be observed that the eigen-values satisfy equation (5.10). The Routh-Hurwicz 
criteria when applied to the matrix M together with the conditions in (5.10) guarantees the local 
existence of E3 as a local attractor.  
   
5.5 Persistence Analysis of HAART 
 
The pathophysiology of HIV-1 persistence during HAART is described elaborately in the paper 
by Pomerantz in [18]. In this subsection, the mathematical criteria for viral persistence during 
HAART will be derived. The interior rest point E10 exists if and only if the system (4.1) exhibits 
persistence. This describes a situation in which the patient survives for a long time with AIDS. It 
is possible during HAART that, the HIV-1 virions cannot be annihilated but instead the system 
persists in a chronic configuration in which the blood plasma levels of the HIV-1 virions co-exist 
with the other clinically measurable parameters such as uninfected CD4+ T cells, the HIV-1 
infected CD4+ T cells, HIV-1 specific CD8+ T cells, and HAART drug molecules. The criteria for 
existence of E10 are listed in the following theorem. 
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Then the system [x1,x2, x3, x4, x5] will persist and the HAART therapeutic outcome E10=
],,,,[ 54321 xxxxx
((((( exists. 
 
Proof. For a proof refer to Nani and Jin [7,15,16].     
   
Clinical Implication 5.5. If uninfected CD4+ T cells, infected CD4+ T cells, the HIV-1 viral 
mRNA copies in the blood plasma, HIV-1 specific cytotoxic CD8+ T cells, and the HAART drug 
concentration are within certain thresholds, then the AIDS patient will live with AIDS. If any of 
the conditions listed in (5.11) are violated, the patient will experience unpredictable therapeutic 
outcomes including full-blown AIDS or spontaneous elimination of HIV-1 virions. 
 
6 Sufficient Criteria for Permanent Cure of AIDS during 
HAART 
 
In this section, the sufficient criteria for permanent annihilation of HIV-1 virions during HAART 
will be derived. The clinically desirable physiological outcomes are E4[x1, 0,0, 0, x5] and E3= [x1, 0, 
0, x4, x5]. It must be recalled that E4 corresponds to the physiological outcome in which HIV-1 
infected CD4+ T cells, the HIV-1 virions in the blood plasma and HIV-1 specific CD8+ T cells are 
eliminated in the blood plasma of the AIDS patient. The sufficient criteria for E4 will be discussed 
first.  
 
6.1 Global Stability of ]ˆ,0,0,0,ˆ[ 514 xxE =  
 
In this subsection, the global stability of ]ˆ,0,0,0,ˆ[ 514 xxE = will be established in the space 
{ }5,4,3,2,10),,,,( 554321 =Φ≤≤ℜ∈=Ω + ixxxxxx ii with iΦ defined in (3.2). 
 
Let  
 { } Ω⊂=Φ≤≤ℜ∈= ++ 5,10),( 25151 ixxxS iixx  
 
The global asymptotic stability of E4 in Ω will be established respect to the flow emanating from
5151 intint xxxx RS ++ ⊂ . 
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The model equations (4.1) correspondingly reduce to the following: 
 
 
 
          
  (6.1) 
  
 
Let N be a neighborhood of a point in Ω⊂+ 51int
xxS . Choose a functional V on N such that 
 
(i) V is positive definite with respect to E4 
(ii) ∞→V  as }5,1{|||| 51 =∂→ + iRx xxi  
(iii) ),( 21 RRCV +∈  and bounded below 
(iv) V is a Liapunov functional for (6.1) 
(v) V(E4) = 0 
(vi) 0>∃η  such that 0)( >ixV wherever )( 4EBxi η∈  for xx ≠ˆ  where  
}||||{)( 51 ηη <−∈= + ixxi xxRxxB  
(v) 0
*
≤V along the solution trajectories of (6.1) 
 
Consider the Liapunov functional: 
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The derivative of V along the solution trajectories of the model equations yields the result: 
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But at a steady state, the following equations hold. 
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and define M ={mij}∈M2X2(R) such that 
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Where XT denotes the transpose of X and 
*
V  is negative definite if satisfy the conditions of m11< 0 
and det (M) > 0. 
 
In particular, the [mij]2x2 are defined as follows: 
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          (6.11) 
 
 
 
 
As the flow dynamics approaches the steady state ]ˆ,0,0,0,ˆ[ 514 xxE = , the following conditions 
hold: 
 
          
  (6.12) 
 
 
 
where 
 
 
 
 
 
In particular, 
 
 
 
 
 
The sufficient criteria for the global asymptotic stability of E4 are specified in the following 
theorem.  
 
Theorem 6.1 Let 
  
(i)  Conditions of Theorem 5.1 holds 
(ii) 
1
1
2
ˆ
b
x ≤ and )ˆ( 11 xGk ′>  
Then the equilibriumE4 is a globally asymptotically stable with respect to the flow emanating 
from Ω⊂+ 51int
xxS . 
 
Proof. The condition (i) of the theorem guarantees the local existence of E4 and establishes that E4 
is a local attractor. The global asymptotic stability of E4 can be shown by invoking the 
Gantmacher criteria [30] for negative definiteness of matrix M as defined in (6.10). In particular, 
*
V is negative definite if m11<0 and detM> 0. But )]ˆ([ˆ 111111 xGkcm ′−−=  is less than zero if 
condition (ii) of the theorem hypothesis holds. However, detM> 0 since the product m11m22> 0. 
Thus, 
*
V < 0 and hence E4 is a global attractor. This completes the proof.   
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Comments on Theorem 6.1 
(i) If 0)ˆ( 1 >xG  then )ˆ( 11 xGk >   and 
1
1
2
ˆ
b
x >  constitute sufficient condition for 
global asymptotic stability of E4. 
(ii) If 0)ˆ( 1 <xG , then 
1
1
2
ˆ
b
x > is a sufficient condition for global asymptotic 
stability of E4. 
(iii) If 0)ˆ( 1 =xG  then 
1
1
2
ˆ
b
x = is a sufficient condition for global asymptotic 
stability of E4.    
 
Clinical Implication 6.1 
 
(i) The function )ˆ( 1xG is a measure of the rate at which the CD4+ T cells (x1) are activated by 
interleukin-2 (IL-2) in an autocrine process when the physiological flow during HAART tends to 
E4. It is possible to attach a biochemical measure to coefficient a1 and b1 of )ˆ( 1xG . This can be 
done as follows: 
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where
1
1
b
Km = is approximately equal to the Michaelis-Menten constant of the CD4
+
 T cells 
activation reaction by interleukin-2, and 
1
1
max b
aV = represents the maximal velocity of the CD4+ T 
cells IL-2 activation reaction. 
 
(ii) Note that k1 is the rate of degradation and decay of the CD4+ T cells during AIDS. Thus the 
theorem implies that if the rate of degradation of CD4+ T cells is greater than the rate of IL-2 
activation of T cells and if in addition, the number of the CD4+ T cells are such that  mKx 2ˆ1 < , 
then the patient will be cured of AIDS. 
 
6.2 Global Stability Analysis for ],,0,0,[ 5413 xxxE =
 
 
In this subsection, the other clinical desirable equilibrium ],,0,0,[ 5413 xxxE = is analyzed. The 
aim is to find the sufficient criteria under which the HIV-1 virions in the blood plasma, the HIV-1 
infected CD4+ T cells are annihilated but the HIV-1 specific CD8+ T cells will persist as memory 
T cells as well as the CD4+ T cells and some drug residues will remain in the AIDS patient. It is 
expected that the CD4+ T cells will eventually repopulate to their carrying capacity whereas the 
drug residues will ultimately dissipate. The analysis will be similar to the preceding one for E4. 
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The restriction of the model equations (4.1) to the space
{ } Ω⊂=Φ≤≤ℜ∈= ++ 5,4,10),,( 3541541 ixxxxS iixxx leads to the following equations. 
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The global stability of ],,0,0,[ 5413 xxxE = will be established with respect to the flow 
emanating from Ω⊂+ 541int
xxxS . 
 
Consider the Liapnnov functional: 
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The derivative of V along the solution curves of the model equations yields the result: 
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The functions G, F, L are continuous, Lebesgue measurable, and of bounded variations.  
 
Let             
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such that XT  denotes the transpose of X. Define C∈M3x3(R) such that  
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Where the [cij]3x3 are defined as follows: 
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As the flow associated with the model equations approaches E3= [ 1x , 0, 0, 4x , 5x ], the matrix 
entries [cij]3x3 have the following form: 
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But it can be shown that  
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In particular, (cf. Nani and Jin [7, 15, 16]) 
 
 
 
     (6.24) 
 
 
 
Similarly, 
 
 
               (6.25) 
 
 
 
Using the specifications in (4.31), the matrix C has the form  
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Theorem 6.2 Let Ω⊂∈ + 541},,{ 541 xxxSxxx . Consider the patho-physiological equilibrium 
E3=[ 1x , 0, 0, 4x , 5x ] such that 
(i) 
14
1
21
bb
x <=  
(ii) 0)( 11 >′> xGk  
 
Then E3=[ 1x , 0, 0, 4x , 5x ] is globally asymptotically stable with respect to the flow emanating 
from Ω⊂+ 541
xxxS . In particular E3 is a global attractor. Consequently, all the HIV-1 virions will 
be permanently annihilated in the AIDS patient.  
 
Proof. The patho-physiological equilibrium E3 is a global attractor if CXXV T=
*
is negative 
definite, or equivalently if the matrix C is negative definite. ButC is negative definite if conditions 
(6.27) (i), (ii), (iii) hold (cf. Gantmacher [30]). Note that (6.27) (i) holds if )( 11 xGk ′> and
1
1
2
b
x < . If 
4
1
1
b
x = , then c12 = 0, which leads to the fulfillment of (6.27) (ii). But c33< 0 and c12 
= 0 whereas c11c22> 0. Thus condition (6.27) (iii) is satisfied. As a result, 
*
V is negative definite. 
Therefore, E3 becomes a global attractor and hence the theorem follows.  
     
Clinical Implications 6.2 
 
(i) Theorem 6.2 gives the sufficient theoretical criteria for the HIV-1 infected CD4+ T cells and 
HIV-1 virions in the blood plasma to be eradicated during HAART. This theorem also provides 
the conditions under which HIV-1 specific CD8+ T cells will persist as memory cells after the 
HAART therapy. 
 
(ii) It is possible to express the conditions of Theorem 6.2 in terms of clinically measurable 
biophysical parameters. By using Taylor expansions of             and           , the condition     
  is approximately equivalent to the expression  
 
          
  (6.28) 
 
This can be interpreted to mean that HAART will cure the AIDS patient if the number density of 
uninfected CD4+ T cells is equal to the Michaelis-Menten constant of the IL-2 activation of the 
CD8+ T cells, which in turn has to be less than twice Michaelis-Menten constant of the IL-2 
activation of the CD4+ T cells.  
 
Corollary 6.2 Suppose 
14
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x ==
 
Then the physiological steady state E3=[ 1x , 0, 0, 4x , 5x ] is a global attractor. 
 
Proof. The conditions (6.27)(i),(ii), (iii) hold if the theorem hypothesis is satisfied. This makes the 
matrix C in (6.19) negative definite. Consequently, the equilibrium becomes global attractor.          
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It is possible to combine Theorem 6.2 and Corollary 6.2 to obtain the combined criteria: 
 
14
1
21
bb
x ≤=
 
 
 
 
7 Simulations and Discussion of Results 
 
Investigative computer simulations will be presented and discussed. These simulations are 
performed using clinically plausible hypothetical patient patho-physiological parametric 
configurations. In particular, the simulations executed for the non-autonomous version of the 
model equations as displayed in (7.1).  
 
 
 
 
 
 
 
 
 
 
 
          
  (7.1) 
 
 
The drug input function f(t) is a technical construct such as to generate the rectangle pulse 
function as shown in Section 3.1. It represents a periodically calibrated transdermal or intra-
venous or caplet drug matrix input with period ω. In particular,  
 
f(t) = f(t+ω)  where ω=6.25 days 
 
It should be noted that the system (4.1) represents HAART during constant continuous caplet drug 
matrix input which is different from the scenarios used in the simulations of this section. 
 
The complete mathematical analysis of the non-autonomous system (7.1) using Floquet Theory 
and Theory of non-linear periodic Dynamical Systems will be done in a future publication. 
 
The numerical estimates used are variations of estimates published in the references: 
[3,4,11,19,20,23]. Some techniques for estimating HIV-I dynamical parameters includeMonte 
Carlo simulation and polynomial regression analysis. The investigative computer simulations 
elucidate several dynamical aspects of HIV-1 AIDS dynamics which are based on the respective 
parametric configurations. The x-axis of the simulation graphs is calibrated in months. 
 
7.1 Simulation Results for Hypothetical AIDS patient #1 
 
The AIDS patho-physiological parametric configuration of hypothetical patient #1 is denoted by 
P1 and exhibited in Table 1. The simulation results show that the HAART protocol impairs HIV-1 
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dynamics in this patient leading to eradication of plasma HIV-1 viremia. The simulation results 
for patient #1 are exhibited in Fig. 1. It can observed that the HIV-1 infected CD4+ T cells are 
eradicated in this patient with the use of anti-AIDS pharmaco-therapeutic drug protocols.  In 
addition, patient #1 experiences HAART- induced immune system reconstitution as the uninfected 
CD4+ T cells and HIV-1 specific CD8+ T cells repopulate. 
 
Table 1. Hypothetical AIDS patient parametric configuration Ρ1 
 
S1 = 800 /day/µl 
a1 = 0.15 /day/cell/µl 
b1 = 0.019 /cell/µl 
α1 = 
0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/cell 
e10 =  
0.0025 cells/day/µl 
x10= 500 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 
0.00001/day/µl/cell 
β1 = 1.05 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.005 
cells/day/µl 
ξ2 = 0.85 
x20 = 400 cells/µl 
 
S3 = 10 /day/µl 
β2 = 0.0015 
virons/CD4+/day/
µl 
β3 = 1.05 
virons/CD4+/day 
α3 = 0.027 
/day/virion/µl 
k3 = 
0.0001/day/µl 
e30 = 0.0001 /day 
η1 = 0.25 
ξ3 = 0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 
/day/cell/µl 
b4 = 0.01/cell/µl 
K2 = 0.0024 
/day/µl 
k4 = 0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2 = 0.45 
x40= 730 cells/µl 
D = 5000 units 
σ0 = 0.5 mg/day 
σ2 = 30 mg/day 
σ3 = 5 mg/day 
λ0 = 5 mg/L 
λ2 = 15 mg/L 
λ3 = 0.025 mg/L 
x50 = 1500 
cells/µl 
k5 = 0.0 /day 
constant 
infusion 
 
 
 
Fig. 1. Simulation results using parametric configuration Ρ1 
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7.2 Simulation Results for Hypothetical AIDS patient #2 
 
The hypothetical AIDS patient #2 is assigned the patho-physiological parametric configuration P2 
as presented in Table 2. The simulation results are exhibited in Fig. 2. It can be observed that this 
patient does have a clinically favorable prognosis under HAART treatment protocol.  The AIDS 
patho – physiodynamics during the given HAART protocol is similar to that for patient #1, as the 
patient #2 also undergoes immune system reconstitution in which the CD4+ T cells repopulate. On 
the other hand, the proliferative activity of the HIV-1 specific CD8+ T cells appears to be down-
regulated. 
 
Table 2. Hypothetical AIDS patient parametric configuration Ρ2 
 
S1 = 800 /day/µl 
a1 = 0.15 
/day/cell/µl 
b1 = 0.005 /cell/µl 
α1 = 
0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/ce
ll 
e10 = 0.0025 
cells/day/µl 
x10= 500 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 
0.00001/day/µl/cell 
β1 = 1.05 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.005 
cells/day/µl 
ξ2 = 0.85 
x20 = 400 cells/µl 
S3 = 10 /day/µl 
β2 = 0.0015    
virions/CD4+/day/µl 
β3 = 1.05 
virons/CD4+/day 
α3 = 
0.027/day/virion/µl 
k3 = 0.0001/day/µl 
e30 = 0.0001 /day 
η1 = 0.25 
ξ3 = 0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 
/day/cell/µl 
b4 = 0.01/cell/µl 
K2 = 0.0024 
/day/µl 
k4 = 0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2 = 0.45 
x40= 730 
cells/µl 
D = 5000 units 
σ0 = 0.5 mg/day 
σ2 = 30 mg/day 
σ3 = 5 mg/day 
λ0 = 5 mg/L 
λ2 = 15 mg/L 
λ3 = 0.025 mg/L 
x50 = 1500 
cells/µl 
k5 = 0.0 /day 
constant 
infusion 
 
 
 
Fig. 2. Simulation results using parametric configuration Ρ2 
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7.3 Simulation Results for hypothetical AIDS patient #3 
 
For this scenario, the patho-physiological parametric configuration of hypothetical patient #3 is as 
shown in Table 3. It must be noted that HIV-1 AIDS dynamics during HAART treatment protocol 
in this patient is exacerbated by contributions from latent reservoirs in contrast to the other 
hypothetical patients. The results of the simulation are shown in Fig. 3. This is a non-equilibrium 
AIDS configuration simulation as it is evident parametric configuration and by the simulation time 
profile. The simulation results show that during the given HAART protocol, the hypothetical 
AIDS patient #3 experiences annihilation of uninfected CD4+T cells and the HIV-1 specific CD8+ 
T cells . Consequently, immune system paralysis occurs as a consequence of the low CD4+ Tcell 
number density, leading to an exponential increase of the blood plasma HIV-1 viremia. This 
simulation represents an unfavorable AIDS outcome during HAART.  
 
Table 3. Hypothetical AIDS patient parametric configuration Ρ3 
 
S1 = 800 /day/µl 
a1 = 0.15 /day/cell/µl 
b1 = 0.003 /cell/µl 
α1 = 0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/cell 
e10 = 0.0025 
cells/day/µl 
x10= 250 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 
0.00001/day/µl/cell 
β1 = 1.05 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.005 
cells/day/µl 
ξ2 = 0.85 
x20 = 400 cells/µl 
S3 = 10 /day/µl 
β2 = 0.0015    
virions/CD4+/day/µl 
β3 = 1.05 
virons/CD4+/day 
α3 = 
0.027/day/virion/µl 
k3 = 0.0001/day/µl 
e30 = 0.0001 /day 
η1 = 0.25 
ξ3 = 0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 
/day/cell/µl 
b4 = 0.002/cell/µl 
K2 = 0.095 /day/µl 
k4 = 0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2 = 0.45 
x40= 730 cells/µl 
D = 5000 units 
σ0 = 1.0 mg/day 
σ2 = 30 mg/day 
σ3 = 5 mg/day 
λ0 = 5 mg/L 
λ2 = 15 mg/L 
λ3 = 0.025 mg/L 
x50 = 3000 
cells/µl 
k5 = 0.0 /day 
Constant 
Infusion 
 
 
 
Fig. 3. Simulation results using parametric configuration Ρ3 
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7.4 Simulation Results for Hypothetical AIDS Patient #4 
 
In this scenario, the drug input is continuous for 6 months and off for another 6 months until 
HAART is discontinued. Fig. 4 presents an unsuccessful HAART therapy for a hypothetical AIDS 
patient with the patho-physiological parametric configuration P4 in Table 4. In this HAART 
scenario, the plasma HIV-1 virions (x3) completely overwhelmed the non-infected CD4+ T helper 
cells (x1) and the HIV-1 specific CD8+ cytotoxic T cells (x4). The HIV-1 infected CD4+ T cells (x2) 
exhibit periodic dynamics and the prognosis for the hypothetical patient is unwholesome (see Nani 
and Jin [15, 16]).  
 
Table 4. Hypothetical AIDS Patient Parametric Configuration Ρ4 
 
S1 = 400 /day/µl 
a1 = 0.09 /day/cell/µl 
b1 = 0.01 /cell/µl 
α1 = 0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/cell 
e10 =  
0.0025 cells/day/µl 
x10= 800 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 
0.00001/day/µl/cell 
β1 = 1.5 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.0005 
cells/day/µl 
ξ2=0.85 
x20 = 400 cells/µl 
 
S3 = 10 /day/µl 
β2 = 
0.0015virons/CD4+/day/µl 
β3 = 1.05 virons/CD4+/day 
α3 = 0.027 /day/virion/µl 
k3 = 0.0001/day 
e30 = 0.0001 /day 
η1= 0.25 
ξ3=0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 
/day/cell/µl 
b4 = 
0.01/cell/µl 
K2 = 0.0024 
/day/µl 
k4 = 
0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2=0.45 
x40= 730 
cells/µl 
D= 3000 units 
σ0= 0.5 mg/day 
σ2= 30 mg/day 
σ3= 5 mg/day 
λ0=5mg/L 
λ2= 10 mg/L 
λ3= 0.025mg/L 
x50 = 1500 
cells/µl 
n = 5 
 
 
 
 
Fig. 4. Simulation results using parametric configuration Ρ4 
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8 Conclusion 
 
The current paper is elaborate and quantitative attempt to construct medically applicable 
mathematic models and derive criteria for efficacious HAART protocol for an AIDS patient. The 
mathematical equations presented in Section 3 are a generalization of the models by Perelson et al. 
[3], Wodarz and Nowak [5], and Tan et al. [23], and many other authors by incorporating more 
clinically relevant parameters of HIV-1 patho-physiodynamics. In particular, interleukim-2 
activation of both CD4+ T cells and CD8+ T cells are implicitly incorporated into the model. In 
this paper, it has been demonstrated that the parameters (a1, b1) and (a4, b4) play a significant role 
in determining the efficacious outcomes of HAART. Clearly, the clinically desirable outcomes are 
the rest points E4 and E3. The criteria for the existence of E4 and E3 are listed respectively in 
Theorem 5.1, and Theorem 5.4.These theorems give the conditions under which both E4 and E3 
can be temporarily or transiently attained. The criteria for E4 and E3 to become global attractors 
are listed in Theorem 6.1 and Theorem 6.2. These theorems, expressed in terms of simple 
clinically attainable and measurable parameters, give the sufficient conditions for the cure of 
AIDS. It will be emphasized that there exist other therapeutic criteria but these are intractable and 
extremely arduous to achieve in a clinical setting.  
 
One essential feature of this research is that the HAART protocol is implemented by using the 
constant continuous intravenous infusion or constant continuous transdermal infusion of the drug. 
As such, the criteria derived in this paper are applies to these settings. The mathematical model for 
intermittent caplet or matrix tablet per oral drug administration can be derived using the non-
autonomous version of the model equations involving the drug input function f(t) discussed by 
Nani and Jin in [7].  
 
The scenarios for clinical failure during HAART due to extreme drug toxicity are represented by 
the rest points E1 and E5.The criteria for these therapeutic outcomes are described by Theorem 5.3 
and Theorem 5.2, respectively. 
 
In conclusion, it must be emphasized that these theoretical results do not constitute clinical cures 
unless the results are implemented together with other pharmacological protocols for the AIDS 
patients. There may exist other theoretical results which are not explicitly discussed in this 
publication. Nevertheless it is essential to note that mathematical modeling has a place in the quest 
for the treatment and cure for HIV-1 induced AIDS. Using the techniques of the mathematical 
modeling and non-linear system analysis, we demonstrated that the activation and kinetic rate 
constants as well as the rates of influx from latently infected reservoir are important factors in the 
determination of the prognosis and therapeutic efficacy of HAART. 
 
The future work will involve the construction of mathematical models which will describe an 
AIDS therapy using HAART in addition to ACI (Active Cellular Immunotherapy) involving 
interleukim-2. Also, in the future, the mathematical model for HAART will include the roles of 
mutations such as the delta32 CCR5 on therapeutic outcomes. 
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